Nektar Therapeutics (NKTR)
74.52
+0.83
(+1.13%)
USD |
NASDAQ |
Aug 25, 13:08
Nektar Therapeutics Max Drawdown (5Y) : 99.39% for July 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| July 31, 2026 | 99.39% |
| June 30, 2026 | 99.39% |
| May 31, 2026 | 99.39% |
| April 30, 2026 | 99.39% |
| March 31, 2026 | 99.39% |
| February 28, 2026 | 99.39% |
| January 31, 2026 | 99.39% |
| December 31, 2025 | 99.39% |
| November 30, 2025 | 99.39% |
| October 31, 2025 | 99.39% |
| September 30, 2025 | 99.39% |
| August 31, 2025 | 99.39% |
| July 31, 2025 | 99.39% |
| June 30, 2025 | 99.39% |
| May 31, 2025 | 99.39% |
| April 30, 2025 | 99.39% |
| March 31, 2025 | 99.39% |
| February 28, 2025 | 99.39% |
| January 31, 2025 | 99.39% |
| December 31, 2024 | 99.39% |
| November 30, 2024 | 99.39% |
| October 31, 2024 | 99.39% |
| September 30, 2024 | 99.39% |
| August 31, 2024 | 99.39% |
| July 31, 2024 | 99.39% |
| Date | Value |
|---|---|
| June 30, 2024 | 99.39% |
| May 31, 2024 | 99.39% |
| April 30, 2024 | 99.39% |
| March 31, 2024 | 99.39% |
| February 29, 2024 | 99.39% |
| January 31, 2024 | 99.39% |
| December 31, 2023 | 99.39% |
| November 30, 2023 | 99.39% |
| October 31, 2023 | 99.39% |
| September 30, 2023 | 99.39% |
| August 31, 2023 | 99.39% |
| July 31, 2023 | 99.39% |
| June 30, 2023 | 99.39% |
| May 31, 2023 | 99.39% |
| April 30, 2023 | 99.39% |
| March 31, 2023 | 99.39% |
| February 28, 2023 | 98.73% |
| January 31, 2023 | 98.13% |
| December 31, 2022 | 98.13% |
| November 30, 2022 | 97.42% |
| October 31, 2022 | 97.20% |
| September 30, 2022 | 97.20% |
| August 31, 2022 | 97.08% |
| July 31, 2022 | 97.08% |
| June 30, 2022 | 97.08% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Elite Pharmaceuticals, Inc. | 87.92% |
| Daré Bioscience, Inc. | 95.72% |
| Aclaris Therapeutics, Inc. | 97.82% |
| Eton Pharmaceuticals, Inc. | 79.94% |
| Journey Medical Corp. | -- |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -35.60 |
| Beta (5Y) | 1.136 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 122.8% |
| Historical Sharpe Ratio (5Y) | -0.2048 |
| Historical Sortino (5Y) | -0.5173 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 36.92% |